EPA-E Lipid Therapy for Hypertriglyceridemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, particularly hypertriglyceridemia and other lipid disorders, often fail to effectively reduce triglyceride levels and improve lipid profiles, especially in patients who have not responded to existing therapies like Lovaza.
Innovation Solution
A pharmaceutical composition predominantly comprising eicosapentaenoic acid ethyl ester, with minimal or no docosahexaenoic acid, administered orally to provide a high concentration of EPA, which helps in reducing triglyceride levels and improving lipid profiles by increasing HDL-C and apo A-I levels, while minimizing LDL-C and triglyceride levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies like Lovaza are used to treat hypertriglyceridemia, then some lipid parameters may be improved, but triglyceride levels are not effectively reduced and lipid profiles are not sufficiently improved
Solution Approach 1:
The patent changes the chemical composition parameters by providing a pharmaceutical composition with a specific fatty acid profile (at least 80% eicosapentaenoic acid ethyl ester, less than 10% docosahexaenoic acid) to achieve superior triglyceride reduction compared to existing therapies
Solution Approach 2:
The patent creates a composite pharmaceutical composition with a optimized blend of fatty acid ethyl esters, specifically designing the ratio of EPA-E to DHA-E to maximize therapeutic effectiveness while minimizing side effects
2Reliability
If high concentration of EPA is administered, then triglyceride levels are reduced and lipid profiles are improved, but the composition complexity increases
Solution Approach 1:
The patent simplifies the composition by establishing clear quantitative parameters (at least 80% EPA-E, less than 10% DHA-E) that define the effective formulation range, making the complex composition manageable through specified concentration thresholds
3Object-affected harmful factors
If conventional fish oil supplements containing both EPA and DHA are used, then some cardiovascular benefits are achieved, but triglyceride reduction is insufficient and LDL-C may increase
Solution Approach 1:
The patent extracts and isolates the most effective component (EPA-E) from conventional fish oil supplements, creating a formulation where EPA-E is the dominant active ingredient to maximize triglyceride reduction while avoiding the limitations of balanced EPA-DHA formulations
Solution Approach 2:
The patent applies local quality by concentrating the therapeutic effect in the specific fatty acid component (EPA-E) that provides the greatest benefit for triglyceride reduction, rather than relying on the average effect of mixed fatty acids
Data Source
AI summary
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.